Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2019

View Archived Issues

DNA damage repair protein Mus81 promotes migration of gastric cancer through regulation of ZEB1

TWEAK/Fn14 is upregulated in Crohn's disease and has a key pathogenic role in ileitis mouse models

Xeris initiates dosing in phase II study of fixed-ratio coformulation of pramlintide and insulin

A pancreatic (pro)enzyme mixture shows high efficacy against human pancreatic cancer stem cells

CAFs 'educated' by GoF p53-mutant pancreatic cancer cells promote metastasis and chemoresistance

Novel glomerulus-on-a-chip for renal disease modeling and drug testing

Boehringer and Inflammasome partner to develop novel therapies for retinal diseases

CStone announces clinical data for CS-1001, CS-1002 and CS-1003

FDA approves Pifeltro and Delstrigo for virologically suppressed adults with HIV-1 infection

Phase I data presented from the phase I/II STERIMGLI trial of durvalumab plus hFSRT

Rottapharm Biotech presents CR-13626, an oral tyrosine kinase inhibitor for the treatment of GBM

Karyopharm presents promising phase II safety and efficacy data for selinexor in rGBM

Lenti-D demonstrates the ability to stabilize neurologic disease progression in phase II/III study

Novartis discovers new endonucleases inhibitors

Reaction Biology Corp. describes HDAC/SIRT inhibitors

U.S. Department of Defense awards research grant to Novan

New PD-1 inhibitors disclosed by Bristol-Myers Squibb

Finding a balance in treating diabetic kidney damage

Beijing Scitech-Mq Pharmaceuticals patents wild-type EGFR, EGFR T790M mutant and HER2 inhibitors

DeNovaMed identifies bacterial acyl carrier protein synthase inhibitors

GenSight reports week 96 data from phase III RESCUE trial of GS-010 in LHON

FDA approves Rybelsus for type 2 diabetes

Immune responses, tumor reductions observed with Bria-IMT and pembrolizumab in phase I/IIa study

Phase IIa study assesses efficacy of vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP

Syndax initiates phase I/II study of SNDX-5613 in relapsed or refractory leukemias

Crysvita approved in Japan for FGF-23-related hypophosphatemic rickets and osteomalacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Aug. 21, 2025.
Ionis gets approval for preventing attacks in rare and genetic HAE
BioWorld
In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and...
Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease
BioWorld Science
Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...
EU, US lock in 15% max Rx tariff, no relief for medtech
BioWorld
No matter what level of tariff the Trump administration ends up imposing on biopharmaceuticals across the world, drugs and their precursors originating in the EU...